From: Evaluating long-term effectiveness of sleeping sickness control measures in Guinea

Parameter | Definition | Value | Reference |
---|---|---|---|

V/H | Number of tsetse flies (V) per human (H) | 17 | [15] |

L/H | Number of NHA (L) per human (H) | 1/6 | [15] |

H | Population size of Boffa East Mainland in 2008 | 14,500 | Unpublished data |

B
_{
V
}
| Tsetse constant birth rate | 0.05/day | [15] |

1/η
_{
V
}
| Duration of pupae stage in tsetse | 20 days | [18] |

\( {\mu}_{V_0} \) | Tsetse death rate without competition | 0.030/day | [15] |

\( {\mu}_{V_1} \) | Death rate competition parameter | 0.0002 | Assumed |

1/σ
_{
V
}
| Susceptibility period in tsetse | 1 day | [15] |

a
| Tsetse biting rate | 0.333/day | [15] |

β
_{
VH
}
| Probability of tsetse bite on human | See Table 2 | Estimated |

β
_{
VL
}
| Probability of tsetse bite on NHA |
min(1-β
_{
VH
},0.71)
| [25] |

1/τ
_{
V
}
| Incubation period in tsetse | 25 days | [15] |

μ
_{
H
}
| Human constant death rate | 4.66e-05 /day | [34] |

β
_{
H
}
| Transmission probability from tsetse to humans | See Table 2 | Estimated |

1/τ
_{
H
}
| Incubation period in humans | 12 days | [15] |

1/γ
_{
H1}
| Stage I infectious period without treatment | 526 days | [35] |

1/γ
_{
H2}
| Stage II infectious period without treatment | 252 days | [36] |

1/δ
_{
H
}
| Immune period in humans after treatment | 50 days | [15] |

β
_{
L
}
| Transmission probability from tsetse to NHA | See Table 2 | Estimated |

β
_{
V
}
| Transmission probability from humans/NHA to tsetse | 0.2 | [2, 15] |

1/τ
_{
L
}
| Incubation period in NHA | 12 days | [15] |

1/γ
_{
L
}
| Infectious period in NHA | 50 days | [15] |

1/δ
_{
L
}
| Immune period in NHA | 50 days | [15] |

ϕ
| Coverage of active surveillance | Varies | - |

ρ
| Probability that a HAT patients gets a positive CATT and then a positive antibody/Trypanolysis test | 0.87 | [1] |

ε
_{1}
| Efficacy of stage I treatment (pentamidine) | 0.94 | [37] |

ε
_{2}
| Efficacy of stage II treatment (nifurtimox-eflornithine) | 0.965 | [38] |

ζ
| Treatment seeking rate of stage II patients | See Table 2 | Estimated |

p
| Probability of death due to stage II treatment failure (nifurtimox-eflornithine) | 0.007 | [38] |